The current financial score of Tandem Diabetes Care Inc is 6.63. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 254.56M, representing a year-over-year increase of 5.77%, while its net profit experienced a year-over-year increase of 59.60%.
The current valuation score of Tandem Diabetes Care Inc is 9.18. Its current P/E ratio is -11.92, which is -72.45% below the recent high of -3.28 and -164.60% above the recent low of -31.53.
The current earnings forecast score of Tandem Diabetes Care Inc is 7.45. The average price target is 29.16, with a high of 50.00 and a low of 18.00.
The current price momentum score of Tandem Diabetes Care Inc is 4.75. Currently, the stock price is trading between the resistance level at 20.49 and the support level at 14.08, making it suitable for range-bound swing trading.
The current institutional shareholding score of Tandem Diabetes Care Inc is 10.00. The latest institutional shareholding proportion is 128.74%, representing a quarter-over-quarter increase of 8.98%.
The current risk assessment score of Tandem Diabetes Care Inc is 5.58. The company's beta value is 1.59. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.